Comparison and Evaluation of Different Treatment Plans with IFRT Field and 6 and 18 MV Energies in Hodgkin’s Lymphoma Involvement Neck and Mediastinum

Tavakoli M. B., Maleki M.²*, Akhavan A.³, Hadisinia T.⁴, Abedi I.⁵, Amouheidari A.⁶

ABSTRACT

Background: Radiotherapy with large mantle field is an effective technique in increasing the risk of secondary cancers among HL (Hodgkin Lymphoma) patients; therefore, it is essential to choose an effective treatment field including the least medical conditions in radiotherapy.

Objective: The present study aimed to plan separate fields for neck and mediastinum using various energies, to compare dose distribution with MLC and to block field formation.

Materials and Methods: In this study, 3D conformal treatments, Siemens Oncor accelerator equipped with multi-leaf collimator (MLC) were performed to create anterior-posterior fields. CT-scan data of 18 female patients with neck and mediastinal involvement was imported in TIGRT treatment planning system, and then treatment plans were introduced.

Results and Conclusion: Using treatment plan 1, photon 6 MV in neck weighting 1 from interior, 0.5 from posterior, photon 18MV in mediastinum weighting 1 from interior and 0.5 from posterior, it was shown that regarding the common treatment plan used with photon 6 MV, mean dose delivered to breast, lung, esophagus and larynx reduced 6, 7, 41 and 10 percent, respectively and uniformity index improved by 10 percent. Using block compared to MLC in all treatment plans offered improved average dose in all organs under study. To protect breast and lung while using MLC and block in the first treatment plan seemed to be more appropriate; however, using blocks in comparison to MLC increased delivered mean dose in all organs under study. Using separate fields with Pb blocks, though, showed smaller increase.

Keywords
Treatment Planning, Radiotherapy, Hodgkin, MLC, 3D Conformal

Introduction

Hodgkin’s is a cancer of the immune cells, which affects lymph nodes and organs. This type of cancer includes 10 percent of all lymphoma and 1 percent of all cancers in the United States of America [1, 2]. Because of the sensitivity of lymphoma to radiation, radiation therapy is the treatment of choice in early stages. Almost 75 percent of patients with Hodgkin Lymphoma (HL), regardless of dis-
ease stage, have long-term survival after treatment [1, 3-5]. However, the increased risk of secondary cancers as a complication of treatment with several factors is undeniable [3, 6, 7]. In 1960, due to the beneficial results from mantle, this field was recognized as a standard for thoracic diaphragm [8]. Considering the studies to this date, it is shown that radiotherapy with large mantle field is an influential factor in increasing the risk of secondary cancers including leukemia, breast and lung in patients with HL [9]. Therefore, selection of an effective treatment with minimal side effects associated with radiation therapy is one of the main issues. Planning a treatment field for patients with HL has significantly changed during the last decade. Recent studies have shown that mere chemotherapy causes translation error of the recurrence of cancer in the lymph nodes involved initially. Nowadays though, combination of chemotherapy with radiation therapy regimens reduces side effects of different treatments as well as reducing the size of radiation field from mantle field to the smaller fields including IFRT and INRT [10].

Involved filed Radiation Therapy (IFRT) was generally defined as radiation to lymph nodes involved and making use of smaller radiation fields decreased side effects in the development of combinational therapies for all stages of Hodgkin’s lymphoma. Nowadays, using radiation therapy with IFRT is common due to less radiation to normal tissues, and it has been known as a standard therapy to combinational treatments [11, 12]. Koh et al. compared mantle and IFRT and suggested that using IFRT reduced the relative risk of breast and lung cancer among women to 65 percent and lung cancer among men to 35 percent [9]. The common method for patients with HL is AP-AP fields and usually in patients with neck and mediastinal involvement using IFRT fields, a general field including mediastinum, supraclavicular and bilateral hila areas correspond to the given area in Perez’s radiation oncology book [9, 12]. However, different thickness in neck and mediastinum could result Non-uniformity in dose distribution as 10% or more [13]. In the present study, we aimed to plan separate fields for neck and mediastinum areas using various energies where total field of neck and mediastinum was divided into two separate parts by MLC, and radiotherapy plans were developed using various weights of 6 and 18 MV photons. The most important role of MLC includes forming automatic fields and, as a result, saving treatment time, reducing production expenses and avoiding or rejecting to keep heavy lead and custom blocks [14-16]. Though, it is still common to use lead blocks in centers where the tools lack MLC in their heads [17] and it causes difficulties such as maintenance, the need to build separate blocks for each patient and increasing treatment costs. Construction of the blocks in some centers lacking MLC is difficult, therefore, ready to use rectangular blocks are used. Consequently, the present study investigated the difference of dose distribution in field planning with rectangular lead blocks and MLC.

Material and Methods

AP-PA fields (parallel opposed) and 6 MV photon beam energy are mostly used in standard treatment plans for most conformal 3D clinical cases [13, 18-23]. The present study made use of 3D conformal with multi-leaf collimator (MLC), Oncor Siemens accelerator to create anterior-posterior fields. Prescriptive dose of 36 Gy was delivered to the normalization point. CT scan information from 18 female patients with neck and mediastinum engagement was used. All data were imported to TIGRT treatment plan system in Milad Hospital, Isfahan, Iran and contouring treatment volume and organs of the breast, lung, thyroid, heart and esophagus was contoured with an oncologist. Treatment planning software will automatically calculate the absorbed dose for each contoured organ after calculating DVH diagram for each treatment planning. When the required information to compare treatment
Treatment Planning in Hodgkin’s Lymphoma

plans was gathered, mean dose delivered to organ at risk, maximum dose and uniformity index were used.

On the first step, four treatment plans with anterior-posterior fields for separate neck and mediastinum fields with MLC were used. As shown in Figure 1, the first field included neck and supraclavicular, and the second field-included mediastinum. Then, 6 and 18 MV photons with various weights were combined to form four treatment plans as following (Table 1).

For the second step, to compare MLC and block, treatment plans implemented by MLC were repeated by prepared blocks. Using prepared fields junction is important if lead blocks are used in multiple fields. The present study used half beam block to avoid overlap in edges of the fields due to different target volumes and contour irregularities. Comfortable setting and non-oblique beam on the surface of the skin are half beam block advantages compared to other common methods. In this method, moving one of the collimator independent jaws toward the middle or using Cerrobend blocks, half of the beam would be blocked causing a non-divergent central field with a right edge at central axis. Figure 2 presents the implementation of separate fields for neck and mediastinum by block.

In both steps, the homogeneity index was defined as maximum point dose divided by the prescribed dose (HI RTOG = Imax/RI). HI RTOG ≤ 2 is considered complaint with protocol [24, 25].

| Number | Filed   | Energy and weight radiation – anterior | Energy and weight radiation – posterior |
|--------|---------|----------------------------------------|----------------------------------------|
| Plan 1 | Neck    | 1-6                                    | 0.5-6                                  |
|        | mediastinal | 1-18                             | 0.5-18                                 |
| Plan 2 | Neck    | 1-6                                    | 1-6                                    |
|        | mediastinal | 1-6                             | 1-6                                    |
| Plan 3 | Neck    | 1-18                                   | 1-18                                   |
|        | mediastinal | 1-18                        | 1-18                                   |
| Plan 4 | Neck    | 1-18                                   | 1-6                                    |
|        | mediastinal | 1-18                        | 0.5-18                                  |

Figure 1: Implementation of separate fields for the neck and mediastinum by MLC A. mediastinal B. neck
Results

Received Doses to Planning Target Volume (PTV)

Considering the data in Table 2, comparing four treatment plans implemented by MLC, the mean dose delivered to PTV in the treatment plan number one (neck field with AP(6-1) PA(6-0.5) and mediastinum AP(18-1)PA(18-0.5)) was less than 2% in comparison to all other treatment plans, though it satisfied criteria treatment plan ±105 for prescribed dose. Considering formula 1, uniformity index from oncology group and radiotherapy (RTOG) (HI\_RTOG≤2), it was seen that the treatment plan number one with 1.09 index offered the best uniformity in therapy volume. Comparing data from Table 3, it was suggested that uniformity at the present treatment plan increased 10% compared to common treatment

| Mean Dose Dmean (cGy) | Plan1 | Plan2 | Plan3 | Plan4 | p-value |
|-----------------------|-------|-------|-------|-------|---------|
| Neck (cGy)            |       |       |       |       |         |
| AP(6-1)PA(6-0.5)      | 88.29 ±7.78 | 119.49 ±8.2 | 93.33 ±10.56 | 107.18 ±6.35 | 0.001 |
| Mediastinal           | 2611.74 ±116.00 | 2679.09 ±135.21 | 2688.76 ±121.01 | 2707.92 ±118.12 | 0.001 |
| Neck (cGy)            | 143.22 ±12.21 | 178.39 ±11.78 | 151.14 ±14.01 | 158.56 ±14.95 | 0.000 |
| Mediastinal           | 157.88 ±15.31 | 180.87 ±14.68 | 196.56 ±19.20 | 242.22 ±23.24 | 0.000 |
| Left Breast (cGy)     | 1300.55 ±61.25 | 1390.11 ±78.26 | 1316.13 ±111.12 | 1363.20 ±55.83 | 0.001 |
| Right Breast (cGy)    | 1080.39 ±119.24 | 1151.65 ±87.35 | 1078.64 ±110.55 | 1126.98 ±97.65 | 0.005 |
| Esophagus             | 510.34 ±28.56 | 564.18 ±23.45 | 518.49 ±63.24 | 551.43 ±45.75 | 0.001 |
| Heart                 | 120.55 ±10.56 | 122.85 ±15.32 | 124.95 ±14.36 | 124.15 ±17.98 | 0.120 |
| Right Lung (cGy)      | 3949.20±89.24 | 4137.46±145.21 | 4040.00±112.36 | 4230.98±114.56 | 0.021 |
| Thyroid               | 1.09±0.89    | 1.14±0.78    | 1.12±0.24    | 1.17±0.45    | 0.102 |
| PTV (cGy)             | 3424.01±135.00 | 3481.93±156.45 | 3465.14±115.62 | 3445.40±96.34 | 0.031 |

Table 2: Mean dose delivered to under study organs at 4 treatment plans, uniformity index, D_{mean} (cGy), D_{max} (cGy) for treatment volume

Figure 2: Implementation of separate fields for the neck and mediastinum by block A. mediastinal B. neck
Treatment Planning in Hodgkin’s Lymphoma

**Table 3**: Comparing mean dose delivered to organs under study, uniformity index, and breast and lung; Volume percentage in three treatment plans

| Mean Dose \( D_{\text{mean}} \) (cGy) | Plan 1 | Plan 2 | Plan 3 |
|---|---|---|---|
| | AP(6-1) | AP(18-1) | Neck: AP(6-1)PA(6-0.5) | Mediastinal: AP(18-1)PA(18-0.5) |
| Left Breast | 153.14 | 122.88 | 88.29 |
| Right Breast | 214.34 | 185.30 | 143.22 |
| Esophagus | 2795.69 | 2772.88 | 2611.74 |
| PTV | 3606.93 | 3538.43 | 3424.01 |
| Heart | 283.91 | 216.73 | 510.34 |
| Larynx | 176.82 | 121.16 | 157.88 |
| Left Lung | 1563.51 | 1485.25 | 1300.55 |
| Right Lung | 1245.36 | 1161.99 | 1080.39 |
| Thyroid | 91.23 | 88.31 | 120.55 |
| Uniformity Index | 1.20 | 1.11 | 1.09 |
| \% \( V_4 \) Left Breast | 5.49 | 7.05 | 3.40 |
| \% \( V_{20} \) Right Breast | 10.92 | 8.36 | 6.01 |
| \% \( V_{20} \) Left Lung | 36.58 | 36.37 | 33.71 |
| \% \( V_{20} \) Right Lung | 28.22 | 27.94 | 26.91 |

with 6MV photon.

**Received Doses to Breast**

Treatment plan 1 showed the smallest mean dose compared to other plans (Table 2). Results from our previous studies showed that mean doses delivered to breast using 6MV photon from anterior and posterior with the same weight were 153 and 214 cGy for right and left, respectively, and using 18MV photon from anterior and posterior were 122 and 185, respectively [26]. Results are shown in Table 3. Mean dose delivered to whole breast decreases by 41 and 27 percent in comparison to other two treatment plans if separate fields in Table 3 are used. Considering the high risk of secondary breast cancer seen in dose 4 Gy [10], it is essential to measure breast \( V_4 \) and even keep it small. According to data from Table 3, using separate fields with 6MV photon at neck and 18MV photon at mediastinum, the volumetric percent of breast receiving 4Gy(\( V_4 \)) at whole breast decreased 42 and 38 percent in comparison to conventional treatments 1 and 2, respectively.

**Received Doses to Lung**

As seen in Table 2, mean dose delivered to whole lung in treatment plan 1 decreased about 4-6 percent compared to other treatment plans. Considering dose and volume tolerance to total lung, \( V_{20} \) <30% and \( D_{\text{mean}}\) <20Gy[19], it was seen that these parameters were smaller using separate fields compared to other treatment plans (See Table 3). According to Table 3, \( V_{20} \) for whole lung decreased in treatment plan 3 by 7 and 6% for plans 1 and 2, respectively.

**Received Doses for heart, Esophagus, Larynx and Thyroid**

According to data from Table 2, mean doses delivered to heart, esophagus, larynx and thyroid in treatment plan 1 were the smallest compared to three other plans. All four plans showed acceptable delivered dose to esophagus (\( D_{\text{mean}} \) <34 Gy); however, mean dose decreased from 2 to 4 % in the treatment plan
1 compared to other treatment plans. Mean dose delivered to heart in treatment plan 1 decreased almost 10% compared to other plans. According to Table 3, mean dose in treatment plan 3 using separate fields at neck and mediastinum for esophagus decreased almost 7%, but increased in heart and thyroid.

Treatment Plans Implemented by Lead Blocks

Four treatment plans implemented by MLC were practiced by block. Among these four plans, using 6MV photon at neck weighting 1 from anterior and 0.5 from posterior, and using 18 MV photon at mediastinum weighting 1 from anterior and 0.5 from posterior were the best treatment plans because they decreased the mean dose delivered to healthy organs and caused more uniform dose distribution in treatment volume. Table 4 shows the results from this treatment plan for more comparison. Considering Table 4, using prepared blocks increased mean dose delivered to whole breast. The increase was 19.6, 45 and 43% in three treatment plans, respectively. Using separate fields (treatment plan 3) caused 3.3% increase in mean dose delivered to whole lung. However, using treatment plan 1 increased mean dose delivery by 29%. As seen in Table 4, using block relative to MLC in all implemented treatment plans caused an increase in mean dose delivered to all organs.

Discussion

Considering the results from Table 2 to protect breast, $D_{\text{mean}} \leq 2$ Gy and minimum dose delivered to breast, it is suggested that treatment plan 1, or using 6 MV photon at neck weighting 1 from anterior and 0.5 from posterior, and 18 MV photon at mediastinum weighting 1 from anterior and 0.5 from posterior, was suitable which corresponded to results from our previous studies [22]. In addition, if forced to use prepared blocks, Table 4, it would be optimal to use treatment plan 3 including using separate fields and decreasing average dose delivered to breast.

According to the results from our previous studies, applying the common treatment of using 6 MV photon from anterior and posterior at

| Mean dose $D_{\text{mean}}$ (cGy) | Plan with Block | Plan with MLC |
|----------------------------------|----------------|---------------|
|                                  | Plan1          | Plan2         | Plan3          | Plan1          | Plan2         | Plan3          |
| Left Breast                      | 207.77         | 219.41        | 149.19         | 153.14         | 122.88        | 88.29          |
| Right Breast                     | 232.95         | 227.52        | 181.17         | 214.34         | 185.30        | 143.22         |
| Esophagus                        | 2854.79        | 2842.12       | 2652.60        | 2795.69        | 2772.88       | 2611.74        |
| PTV                              | 3616.48        | 3573.52       | 3499.21        | 3606.93        | 3538.43       | 3424.01        |
| Heart                            | 327.48         | 270.84        | 281.78         | 283.91         | 216.73        | 510.34         |
| Larynx                           | 232.05         | 174.67        | 288.79         | 176.82         | 121.16        | 157.88         |
| Left Lung                        | 1623.24        | 1520.15       | 1350.46        | 1563.51        | 1485.25       | 1300.55        |
| Right Lung                       | 2013.69        | 1208.10       | 1110.01        | 1245.36        | 1161.99       | 1080.39        |
| Thyroid                          | 135.23         | 163.75        | 147.05         | 91.23          | 88.31         | 120            |

Table 4: Comparison of Mean dose delivered to studied organs, with and without MLC
the same weight could offer a better coverage to treatment volume [26]. Though, using treatment plan 3, as this table shows, decreased average dose compared to other plans, but satisfied treatment-planning criterion (±105 prescribed dose) and caused acceptable coverage. Moreover, treatment plan 3 or using separate fields was the best plan to protect lung considering the smallest $V_{20}$ and $D_{mean}$. According to data in Table 3 and considering all treatment planning criteria such as better coverage of treatment volume (maximum dose delivered to treatment volume), uniform dose distribution and minimum dose delivered to healthy organs surrounding tumors, it was suggested that treatment plan 1 or using 6 MV photon at neck weighting 0.5 from anterior and 1 from posterior, and 18 MV photon at the same weight for anterior and posterior was the most suitable plan.

In conclusion, Table 3 represents the comparison of three treatment plans selected and implemented by MLC. Since ease of treatment planning, treatment setting and treatment calculations included planning considerations, in a compromise to choose treatment technique using treatment plan 3 in Table 3, or using separate fields with 6 and 18 MV photons with MLC, could reduce mean dose delivered to organs by some percent and reduce $V_{20}$ volume percentage in lung and $V_{4}$ in breast and also therefore could provide better uniformity. Nevertheless, due to setup, treatment plan 3 was more time consuming compared to plans 1 and 2 due to its layout. Therefore, in clinical applications in more crowded centers, it is more practical to use treatment plan 2 (using 18 MV photon with the same weights anterior and posterior) in neck and mediastinum fields which offers better agreement with treatment plan criteria in comparison to plan 1.

Using rectangular blocks to form a field instead of MLC is still very common in many health care centers. However, due to the inability of these blocks in strict compliance with complex fields, probability of exposure of healthy organs increased and as a result, secondary cancers would be more probable if they were used. According to the results from the present study, although in comparison to MLC, using blocks to form a field increased mean dose to all organs, using separate fields with lead blocks to form a field decreased mean doses delivered to organs. Therefore, in health care centers using lead blocks, making use of separate fields at neck and mediastinum could reduce doses distributed to breast, heart, esophagus, larynx and thyroid due to better field correspondence to treatment volume. Accordingly, it effectively decreases the risk of secondary cancer resulting from radiation to whole field of neck and mediastinum.

Conflict of Interest
None

References
1. Villasboas JC, Ansell SM. Recent advances in the management of Hodgkin lymphoma. F1000Res. 2016;5. doi.org/10.12688/f1000research.8301.1. PubMed PMID: 27158471. PubMed PMCID: 4850875.
2. Steven H, Swerdlow EC, Harris NL, Jaffe ES, Pirelli S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International agency for research on cancer. Lyon. 2008:274-88.
3. Norval EJ, Raubenheimer EJ. Second malignancies in Hodgkin’s disease: A review of the literature and report of a case with a secondary Lennert’s lymphoma. J Oral Maxillofac Pathol. 2014;18:S90-5. doi.org/10.4103/0973-029X.141332. PubMed PMID: 25364188. PubMed PMCID: 4211247.
4. Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, et al. High incidence of late effects found in Hodgkin’s lymphoma survivors, following recall for breast cancer screening. Br J Cancer. 2006;94:469-72. doi.org/10.1038/sj.bjc.6602974. PubMed PMID: 16465193. PubMed PMCID: 2361189.
5. Glicksman AS, Pajak TF, Gottlieb A, Nissen N, Stutzman L, Cooper MR. Second malignant neoplasms in patients successfully treated for Hodgkin’s disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982;66:1035-44. PubMed PMID: 6951632.
6. Koletsky AJ, Bertino JR, Farber LR, Prosnitz LR, Kapp DS, Fischer D, et al. Second neoplasms in patients with Hodgkin’s disease following combined modality therapy--the Yale experience. *J Clin Oncol.* 1986;4:311-7. doi.org/10.1200/JCO.1986.4.3.311. PubMed PMID: 3905674.

7. Arsenneau JC, Canellos GP, Johnson R, DeVita VT, Jr. Risk of new cancers in patients with Hodgkin's disease. *Cancer.* 1977;40:1912-6. doi.org/10.1002/1097-0142(19770710)40:4+<1912::AID-CNCR2822008233.0.CO;2-D. PubMed PMID: 907993.

8. Poston GJ, Beauchamp D, Ruers T. Textbook of surgical oncology: CRC Press; 2007.

9. Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang BS, et al. Comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. *Radiat Oncol.* 2007;2:13. doi.org/10.1186/1748-717X-2-13. PubMed PMID: 17362522. PubMed PMID: 1847517.

10. Brady LW, Perez CA, Perez C, Brady L. Principles and Practice of radiation oncology: Lippincott Williams & Wilkins; 2013.

11. Halpering E, Perez CA, Brady L. Principles and Practice of radiation Oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.

12. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. *J Clin Oncol.* 2004;22:2835-41. doi.org/10.1200/JCO.2004.12.170. PubMed PMID: 15199092.

13. Specht L, Ng AK. Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. Radiotherapy for Hodgkin Lymphoma: Springer; 2011. p. 7-20.

14. Yan G, Liu C, Simon TA, Peng LC, Fox C, Li JG. On the sensitivity of patient-specific IMRT QA to MLC positioning errors. *J Appl Clin Med Phys.* 2009;10:2915. doi.org/10.1120/jacmp.v10i1.2915. PubMed PMID: 19223841.

15. Topolnjak R, van der Heide UA. An analytical approach for optimizing the leaf design of a multi-leaf collimator in a linear accelerator. *Phys Med Biol.* 2003;53:3007-21. doi.org/10.1088/0031-9155/53/11/017. PubMed PMID: 18490812.

16. Cheng CW, Das JJ, Steinberg T. Role of multileaf collimator in replacing shielding blocks in radiation therapy. *Int J Cancer.* 2001;96:385-95. doi.org/10.1002/ijjc.1038. PubMed PMID: 11745510.

17. Tajiri M, Sunaoka M, Fukumura A, Endo M. A new radiation shielding block material for radiation therapy. *Med Phys.* 2004;31:3022-3. doi.org/10.1118/1.1809767. PubMed PMID: 15587655.

18. Khan, F.M. and J.P. Gibbons, Khan’s the physics of radiation therapy. 2014: Lippincott Williams & Wilkins.

19. Hoskin P, Diaz P, Williams M, Lucraft H, Bayne M. Recommendations for the use of radiotherapy in nodal lymphoma. *Clinical Oncology.* 2013;25:49-58. doi.org/10.1016/j.clon.2012.07.011.

20. De Sanctis V, Bolzan C, D'Arienzo M, Bracci S, Fanelli A, Cox MC, et al. Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? *Radiat Oncol.* 2012;7:129. doi.org/10.1186/1748-717X-7-129. PubMed PMID: 22857015. PubMed PMID: 3484070.

21. Cella L, Liuzzi R, Magliulo M, Conson M, Camera L, Salvatore M, et al. Radiotherapy of large target volumes in Hodgkin’s lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. *Radiat Oncol.* 2010;5:33. doi.org/10.1186/1748-717X-5-33. PubMed PMID: 20459790. PubMed PMID: 2881006.

22. Schill S, Kampfer S, Hansmeier B, Nieder C, Geinitz H, editors. Sparing of critical organs in radiotherapy of mediastinal lymphoma. World Congress on Medical Physics and Biomedical Engineering, September 7-12, 2009, Munich, Germany; 2009: Springer.

23. Kumar PP, Good RR, Jones EO, Somers JE, McAnulty BE, McCaul GF, et al. Extended-field isocentric irradiation for Hodgkin's disease. *J Natl Med Assoc.* 1987;79:969-80. PubMed PMID: 3312619. PubMed PMID: 2625591.

24. Voong KR, McSpadden K, Pinnix CC, Shihadeh F, Reed V, Salehpour MR, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. *Radiat Oncol.* 2014;9:94. doi.org/10.1186/1748-717X-9-94. PubMed PMID: 24735767. PubMed PMID: 4013438.

25. Feuvret L, Noel G, Mazeron JJ, Bei P. Conformity index: a review. *Int J Radiat Oncol Biol Phys.* 2006;64:333-42. doi.org/10.1016/j.ijrobp.2005.09.028. PubMed PMID: 16414369.

26. Tavakoli MB, Maleki M, Akhavan A, Amoohheidary A, Abedi E, Hadsisina T. Comparing different treatment plans in radiotherapy of Hodgkin’s disease involving neck and Mediastinum, using “Parallel-opposite fields” method. *Journal of Isfahan Medical School.* 2017;35:381-6. [in Persian]